Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.610
-0.050 (-1.88%)
Nov 21, 2024, 2:14 PM EST - Market open
Aerovate Therapeutics Employees
Aerovate Therapeutics had 51 employees as of December 31, 2023. The number of employees increased by 8 or 18.60% compared to the previous year.
Employees
51
Change (1Y)
8
Growth (1Y)
18.60%
Revenue / Employee
n/a
Profits / Employee
-$1,659,039
Market Cap
75.36M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 51 | 8 | 18.60% |
| Dec 31, 2022 | 43 | 27 | 168.75% |
| Dec 31, 2021 | 16 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| P3 Health Partners | 400 |
| I-Mab | 220 |
| OptimizeRx | 136 |
| Armata Pharmaceuticals | 66 |
| BioAtla | 65 |
| ESSA Pharma | 50 |
| Werewolf Therapeutics | 47 |
| Quince Therapeutics | 32 |
AVTE News
- 16 days ago - AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE - Business Wire
- 20 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - PRNewsWire
- 4 months ago - Aerovate Therapeutics to Explore Strategic Alternatives - GlobeNewsWire
- 5 months ago - Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC - GlobeNewsWire
- 5 months ago - Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm - GlobeNewsWire
- 5 months ago - Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire
- 5 months ago - Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market - Seeking Alpha
- 6 months ago - Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference - GlobeNewsWire